Harold Burstein, MD
Enriched profileProfessor of Medicine, Harvard Medical School · Dana-Farber Cancer Institute
Harold Burstein is Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. OpenAlex indexes 441 publications with 50,939 citations (h-index 102); ClinicalTrials.gov lists 12 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 15 Oct 2026
Overview
Updated 16 Oct 2026
Harold Burstein, MD PHD, is Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. The public record shows 441 publications with 50,939 citations (h-index 102), centered on Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 2 companies, 3 NIH-funded awards (2009–2026).
- Most recent indexed publication: 2025 · Clinical cancer research
- Top research focus: Breast Cancer Treatment Studies
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 14 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 239.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer
Sponsor: Harold J. Burstein, MD, PhD
- Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
Sponsor: National Cancer Institute (NCI)
- Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer
Sponsor: Harold J. Burstein, MD, PhD
Industry payments
Updated 16 Oct 2026
2 companies reported payments to CMS in program years 2021–2023. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20232 payments
- AstraZeneca Pharmaceuticals LPProgram year20222 payments
- Gilead Sciences, Inc.Program year20211 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Aromatase Inhibitor62.9%Letrozole61%Anastrozole30%Exemestane10%Part D<11 patientsEstrogen Agonist/Antagonist26.7%Tamoxifen Citrate100%Part D≥35 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
3 NIH research awards on record, funded 2009–2026 per NIH RePORTER. The latest:
- NCTN Lead Academic Participating Site at Dana-Farber/Harvard Cancer Consortium
Dana-Farber Cancer Inst
FY2026$997,843UG1CA233180 - NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
Dana-Farber Cancer Inst
FY2025$1,048,779UG1CA233180 - NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
Dana-Farber Cancer Inst
FY2024$1,048,778UG1CA233180
Congress activity
Updated 16 Oct 2026
57 congress contributions (2004–2025) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.
Clinical cancer research
Clinical Trial2025 - Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response.
Journal of clinical oncology
Article2024
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyArticle1,623 citations2020
- 04Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in OncologyArticle1,617 citations2018
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/harold-burstein-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Harold-Burstein
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/DrHBurstein
Mentions by others
where others cite or feature them- X / Twitter
x.com/DFCI_BreastOnc/status/1857536576349237392
- YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- MD
Harvard Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - PhD in Cellular Immunology
Harvard University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Master's degree in History of Science
Harvard University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- Fellow
American College of Physicians (FACP)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →society.asco.org ↗ - Associate Editor for Cancer Education
Journal of Clinical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →talemhealth.digitellinc.com ↗ - Chair
ASCO Guideline on Endocrine Therapy for Breast Cancer
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →talemhealth.digitellinc.com ↗ - Member
National Comprehensive Cancer Network (NCCN) Breast Cancer Panel
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →talemhealth.digitellinc.com ↗ - Member
St. Gallen Breast Cancer Panel
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →talemhealth.digitellinc.com ↗ - Member
Alliance Breast Cancer Committee (formerly CALGB Breast Cancer Committee)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →talemhealth.digitellinc.com ↗ - Member
ASCO Health Services Research Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pri-med.com ↗ - Member
ASCO Clinical Research Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pri-med.com ↗ - Member
National Quality Forum Breast Cancer Technical Panel
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pri-med.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →learn.hms.harvard.edu ↗
Media & interviews
press, podcasts and appearances- Guest
"The Drive" with Peter Attia, Episode #278: "Breast cancer: how to catch, treat, and survive breast cancer"
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →peterattiamd.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Hope Rugo, MD
City of Hope
Dennis Slamon, MD
University of California, Los Angeles